Health Catalyst appoints Steve Nelson to its Board of Directors, enhancing leadership amid strategic transformation efforts.
Quiver AI Summary
Health Catalyst, Inc. announced the appointment of Steve Nelson, Executive Vice President and President of Aetna, to its Board of Directors, effective May 1, 2026. This move follows other leadership changes at the company as part of a strategy to transform healthcare systems by addressing cost, clinical outcomes, and consumer experience. Ben Albert, CEO of Health Catalyst, expressed confidence in Nelson's extensive experience in the healthcare sector, which includes leadership roles at major health organizations and a focus on value-based care. Nelson emphasized his enthusiasm for joining Health Catalyst at a significant time, highlighting the company's commitment to AI-driven solutions that tackle critical challenges in healthcare.
Potential Positives
- Steve Nelson, former Executive Vice President and President of Aetna, joins the Board of Directors, bringing extensive experience and a unique perspective from the healthcare insurance sector.
- Nelson's appointment is part of a strategic leadership transition aimed at enhancing Health Catalyst's ability to assist health systems in addressing critical challenges such as cost control and clinical quality improvement.
- The company’s focus on AI-enabled technology solutions is underscored by Nelson's belief that these innovations directly address foundational challenges faced by health systems.
- The collaboration with a seasoned executive like Nelson enhances Health Catalyst's credibility and potential to improve outcomes for their healthcare clients.
Potential Negatives
- Steve Nelson's appointment comes amid significant leadership changes, which may indicate instability or uncertainty within the company's strategic direction.
- The press release highlights potential risks associated with forward-looking statements, suggesting that actual future performance could differ significantly from what is projected.
- There is no mention of specific strategies or metrics that will demonstrate the effectiveness of the new leadership appointments, which could leave stakeholders questioning the company's future trajectory.
FAQ
Who has been appointed to Health Catalyst's Board of Directors?
Steve Nelson, Executive Vice President and President of Aetna, has been appointed to the Board.
When does Steve Nelson officially join the Board?
Steve Nelson officially joins the Board of Directors on May 1, 2026.
What is Health Catalyst's main focus as a company?
Health Catalyst focuses on accelerating measurable improvement for health systems, addressing cost, clinical outcomes, and consumer experience.
What prior experience does Steve Nelson bring to Health Catalyst?
Nelson has extensive experience in healthcare, including roles at Aetna, ChenMed, Duly Health and Care, and UnitedHealthcare.
What is the significance of Steve Nelson's appointment?
Nelson's appointment strengthens Health Catalyst's leadership by bringing valuable insights to address health systems' challenges.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HCAT Insider Trading Activity
$HCAT insiders have traded $HCAT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $HCAT stock by insiders over the last 6 months:
- JULIE LARSON-GREEN sold 47,997 shares for an estimated $128,348
- BENJAMIN LANDRY (General Counsel) sold 27,425 shares for an estimated $72,327
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$HCAT Revenue
$HCAT had revenues of $74.7M in Q4 2025. This is a decrease of -6.19% from the same period in the prior year.
You can track HCAT financials on Quiver Quantitative's HCAT stock page.
$HCAT Hedge Fund Activity
We have seen 59 institutional investors add shares of $HCAT stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRIMECAP MANAGEMENT CO/CA/ removed 1,028,649 shares (-75.1%) from their portfolio in Q4 2025, for an estimated $2,458,471
- RA CAPITAL MANAGEMENT, L.P. added 793,749 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,897,060
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 525,279 shares (-3.9%) from their portfolio in Q4 2025, for an estimated $1,255,416
- MILLENNIUM MANAGEMENT LLC removed 504,693 shares (-31.8%) from their portfolio in Q4 2025, for an estimated $1,206,216
- HIGHMARK WEALTH MANAGEMENT LLC added 431,200 shares (+139.0%) to their portfolio in Q4 2025, for an estimated $1,030,568
- MOORE CAPITAL MANAGEMENT, LP removed 398,857 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $953,268
- CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. removed 389,328 shares (-40.1%) from their portfolio in Q4 2025, for an estimated $930,493
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$HCAT Price Targets
Multiple analysts have issued price targets for $HCAT recently. We have seen 6 analysts offer price targets for $HCAT in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Stan Berenshteyn from Wells Fargo set a target price of $1.0 on 03/18/2026
- Sarah James from Cantor Fitzgerald set a target price of $3.0 on 03/13/2026
- David Grossman from Stifel set a target price of $2.0 on 03/13/2026
- Richard Close from Canaccord Genuity set a target price of $2.0 on 03/13/2026
- Jeff Garro from Stephens & Co. set a target price of $2.0 on 03/13/2026
- Daniel Grosslight from Citigroup set a target price of $1.75 on 03/13/2026
Full Release
SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Steve Nelson, Executive Vice President and President of Aetna, a CVS Health company, has been appointed to its Board of Directors, effective May 1, 2026.
Nelson’s appointment follows the naming of Ben Albert as CEO and Justin Spencer as Chairman of the Board earlier this year, continuing a deliberate pattern of leadership moves designed to accelerate the company's transformation– executing on a single, coordinated strategy to help health systems address cost, clinical outcomes, and consumer experience as one imperative.
“Steve has seen the healthcare ecosystem from every angle that matters,” said Ben Albert, CEO of Health Catalyst, “as a leader of one of the largest health insurers shaping U.S. healthcare, as a leader of large premier value-based care and multi-specialty provider organizations, and as an executive navigating the pressure points that health systems face every day. We believe that perspective is exactly what we need to execute on our commitment to be the intelligence partner health systems rely on to make their most consequential decisions. We are grateful to have him.”
In his current role at Aetna, a CVS Health company, Nelson has championed stronger provider partnerships and a less transactional approach to healthcare. Previously, he served as Chief Executive Officer of ChenMed and led Duly Health and Care, building and scaling delivery models where health outcomes, provider experience, cost discipline, clinical performance, and consumer engagement operated as a single integrated strategy. His earlier tenure as CEO of UnitedHealthcare, combined with other executive and board roles across both public and private healthcare organizations, gives him deep understanding on the forces shaping how health systems are reimbursed, evaluated, and held accountable. He brings to Health Catalyst's board a breadth of perspective deeply rooted in what health system clients need their intelligence partner to understand.
“I am honored to join Health Catalyst's board at such a pivotal moment for the company and for healthcare. Ben and the team are delivering AI-enabled technology solutions that directly address the foundational challenges health systems face: controlling costs, improving clinical quality, and elevating the consumer and provider experience. This is the kind of work that moves the industry forward, and I believe this is the right moment to be part of it,” said Steve Nelson.
ABOUT HEALTH CATALYST
Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company that accelerates measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the impact of Mr. Nelson joining the Board. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.
Important risks and uncertainties that could cause actual results to differ materially from Health Catalyst's expectations, plans and prospects. For a detailed discussion of the risk factors that could affect Health Catalyst's actual results, please refer to the risk factors identified in Health Catalyst's SEC reports, including, but not limited to, the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, filed with the SEC on November 10, 2025 and the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025 and amended on April 30, 2025. All information provided in this release and in the attachments is as of the date hereof, and Health Catalyst undertakes no duty to update or revise this information unless required by law.